Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 13

Results For "compliance"

403 News Found

OneSource and BRL ink technology licensing agreement to deliver high-concentration biologics subcutaneously
News | August 06, 2024

OneSource and BRL ink technology licensing agreement to deliver high-concentration biologics subcutaneously

Revolutionary technology will further boost OneSource’s scientific services offerings


Strides Pharma posts Q1 FY25 PAT at Rs. 68.3 Cr
News | August 01, 2024

Strides Pharma posts Q1 FY25 PAT at Rs. 68.3 Cr

The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY


USFDA completes inspection at Biocon Biologics’ facilities in Bengaluru
News | July 29, 2024

USFDA completes inspection at Biocon Biologics’ facilities in Bengaluru

The inspection scope included 6 separate Biologics manufacturing units comprising 4 Drug Substance and 2 Drug Product manufacturing plants


Piramal Pharma Q1 FY25 net loss narrows
News | July 26, 2024

Piramal Pharma Q1 FY25 net loss narrows

EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24


Avallano releases AI-driven ProtocolCopilot
News | July 17, 2024

Avallano releases AI-driven ProtocolCopilot

ProtocolCopilot leverages advanced artificial intelligence to streamline the process of understanding and adhering to clinical research protocols


Lupin receives EIR from USFDA for its Dabhasa  facility
Drug Approval | July 13, 2024

Lupin receives EIR from USFDA for its Dabhasa facility

The facility is a part of Lupin Manufacturing Solutions


Aster Health Academy announces strategic partnerships with premier Hospitals across India
News | July 08, 2024

Aster Health Academy announces strategic partnerships with premier Hospitals across India

The academy has secured partnerships with 15 esteemed hospitals


Avallano appoints Michael A. Ibara as Chief Strategy Officer
News | July 03, 2024

Avallano appoints Michael A. Ibara as Chief Strategy Officer

Ibara will drive AI-powered clinical research innovation


Jubilant Ingrevia receives EIR from USFDA for Unit-1 at Bharuch
Drug Approval | June 28, 2024

Jubilant Ingrevia receives EIR from USFDA for Unit-1 at Bharuch

This existing GMP compliant facility, located at Bharuch (Unit-1) with ongoing expansion part of the company's strategic capex initiative